Cyclin D1 and p21 is elevated in the giant cells of giant cell tumors

Journal of Orthopaedic Research

Volumn 24, Issue 3, 2006, Pages 428-437

  Kandel, R ^a   Li, S Q ^a   Bell, R ^a   Wunder, J ^a   Ferguson, P ^a   Kauzman, A ^b   Diehl, J A ^c   Werier, J ^d  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cyclin D1; Gene expression; Giant cell tumor; p21

Indexed keywords

CYCLIN D1; PROTEIN P21; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MESSENGER RNA; RNA;

ARTICLE; BONE TUMOR; CARCINOGENESIS; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; GIANT CELL; GIANT CELL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; STATISTICAL SIGNIFICANCE; CELL CULTURE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OSTEOCLASTOMA; PATHOLOGY;

BONE NEOPLASMS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION REGULATION, NEOPLASTIC; GIANT CELL TUMOR OF BONE; GIANT CELLS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED;

EID: 33645738989     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20036     Document Type: Article

References (55)

1. Diehl JA. 2002. Cycling to cancer with cyclin D1. Cancer Biol Ther 1:226-231.
2. Kauzman A, Li SQ, Bradley G, et al. 2003. Cyclin alterations in giant cell tumor of bone. Mod Pathol 16:210-218.
3. Sherr CJ. 2000. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 60:3689-3695.
4. Fu M, Wang C, Li Z, et al. 2004. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 145:5439-5447.
5. Sherr CJ, Roberts JM. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501-1512.
6. Dotto GP. 2000. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 1471: M43-M56.
7. Cheng M, Olivier P, Diehl JA, et al. 1999. The p21(Cip1) and p27(Kip1) CDK "inhibitors" are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 18:1571-1583.
8. Coqueret O. 2003. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 13:65-70.
9. Alt JR, Cleveland JL, Hannink M, et al. 2000. Diehl JA. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 14:3102-3114.
10. Diehl JA, Cheng M, Roussel MF, et al. 1998. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12:3499-3511.
11. Diehl JA, Sherr CJ. 1997. A dominant-negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase 4 (CDK4) and its phosphorylation by CDK-activating kinase. Mol Cell Biol 17: 7362-7374.
12. Casanovas O, Miro F, Estanyol JM, et al. 2000. Osmotic stress regulates the stability of cyclin D1 in a p38SAPK2-dependent manner. J Biol Chem 275:35091-35097.
13. Liang J, Slingerland JM. 2003. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2:339-345.
14. Alt JR, Gladden AB, Diehl JA. 2002. p21(Cip1) Promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export. J Biol Chem 277: 8517-8523.
15. Germain D, Russell A, Thompson A, et al. 2000. Ubiquitination of free cyclin D1 is independent of phosphorylation on threonine 286. J Biol Chem 275:12074-12079.
16. Senderowicz AM. 2003. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms. Cancer Chemother Pharmacol 52(Suppl 1):S61-S73.
17. LeMarchand L, Seifried A, Lum-Jones A, et al. 2003. Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer. JAMA 290:2843-2848.
18. Wang L, Habuchi T, Mitsumori K, et al. 2003. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer 103:116-120.
19. Wang L, Habuchi T, Takahashi T, et al. 2002. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis 23:257-264.
20. Hinds PW, Dowdy SF, Eaton EN, et al. 1994. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 91:709-713.
21. Lovec H, Sewing A, Lucibello FC, et al. 1994. Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene 9: 323-326.
22. Rodriguez-Puebla ML, LaCava M, Conti CJ. 1999. Cyclin D1 overexpression in mouse epidermis increases cyclin-dependent kinase activity and cell proliferation in vivo but does not affect skin tumor development. Cell Growth Differ 10:467-472.
23. Wang TC, Cardiff RD, Zukerberg L, et al. 1994. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669-671.
24. Nelsen CJ, Kuriyama R, Hirsch B, et al. 2005. Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy. J Biol Chem 280:768-776.
25. Lung JC, Chu JS, Yu JC, et al. 2002. Aberrant expression of cell-cycle regulator cyclin D1 in breast cancer is related to chromosomal genomic instability. Genes Chromosomes Cancer 34:276-284.
26. Kauzman A, Li SQ, Bradley G, et al. 2004. Central giant cell granuloma of the jaws: assessment of cell cycle proteins. J Oral Pathol Med 33:170-176.
27. Mirra J. 1989. Bone tumors clinical, radiologic and pathologic correlations, 1st ed. Philadelphia: Lea & Febiger.
28. Sakkers RJ, van der Heul RO, Kroon HM, et al. 1997. Late malignant transformation of a benign giant-cell tumor of bone. A case report. J Bone Joint Surg Am 79:259-262.
29. Izzo JG, Papadimitrakopoulou VA, Li XQ, et al. 1998. Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification. Oneogene 17:2313-2322.
30. Oursler MJ, Pederson L, Fitzpatrick L, et al. 1994. Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. Proc Natl Acad Sci USA 91:5227-5231.
31. Lebwohl DE, Muise-Helmericks R, Sepp-Lorenzino L, et al. 1994. A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line. Oncogene 9:1925-1929.
32. Albanese C, Johnson J, Watanabe G, et al. 1995. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 270:23589-23597.
33. Boulon S, Dantonel JC, Binet V, et al. 2002. Oct-1 potentiates CREB-driven cyclin D1 promoter activation via a phospho-. Mol Cell Biol 22:7769-7779.
34. Joyce D, Albanese C, Steer J, et al. 2001. NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 12:73-90.
35. Magne S, Caron S, Charon M, et al. 2003. STAT5 and Oct-1 form a stable complex that modulates cyclin D1 expression. Mol Cell Biol 23:8934-8945.
36. Rimerman RA, Gellert-Randleman A, Diehl JA. 2000. Wnt1 and MEK1 cooperate to promote cyclin D1 accumulation and cellular transformation. J Biol Chem 275:14736-145742.
37. Shtutman M, Zhurinsky J, Simcha I, et al. 1999. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96:5522-5527.
38. Coleman ML, Marshall CJ, Olson MF. 2003. Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. EMBO J 22:2036-2046.
39. Hiyama H, Iavarone A, LaBaer J, et al. 1997. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. Oncogene 14:2533-2542.
40. Kim AL, Gautier J, Bickers DR, et al. 2002. Reduced cyclin D1 ubiquitination in UVB-induced murine squamous cell carcinomas. Biochem Biophys Res Commun 298:377-382.
41. Masui F, Ushigome S, Fujii K. 1998. Giant cell tumor of bone: an immunohistochemical comparative study. Pathol Int 48:355-361.
42. Sulh MA, Greco MA, Jiang T, et al. 1996. Proliferation index and vascular density of giant cell tumors of bone: are they prognostic markers? Cancer 77:2044-2051.
43. Stacey DW. 2003. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol 15:158-163.
44. Maga G, Hubscher U. 2003. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci 116:3051-3060.
45. Atadja P, Wong H, Veillete C, et al. 1995. Overexpression of cyclin D1 blocks proliferation of normal diploid fibroblasts. Exp Cell Res 217:205-216.
46. Gottifredi V, McKinney K, Poyurovsky MV, et al. 2004. Decreased p21 levels are required for efficient restart of DNA synthesis after S phase block. J Biol Chem 279:5802-5810.
47. Oku T, Ikeda S, Sasaki H, et al. 1998. Functional sites of human PCNA which interact with p21 (Cip1/Waf1), DNA polymerase delta and replication factor C. Genes Cells 3:357-369.
48. LaBaer J, Garrett MD, Stevenson LF, et al. 1997. New functional activities for the p21 family of CDK inhibitors. Genes Dev 11:847-862.
49. Sankar U, Patel K, Rosol TJ, et al. 2004. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1. J Bone Miner Res 19:1339-1348.
50. Okahashi N, Murase Y, Koseki T, et al. 2001. Osteoclast differentiation is associated with transient upregulation of cyclin-dependent kinase inhibitors p21(WAF1/CIP1) and p27(KIP1). J Cell Biochem 80:339-345.
51. Meiyanto E, Hoshijima M, Ogawa T, et al. 2001. Osteoclast differentiation factor modulates cell cycle machinery and causes a delay in s phase progression in RAW264 cells. Biochem Biophys Res Commun 282:278-283.
52. Andres V, Walsh K. 1996. Myogenin expression, cell cycle withdrawal, and phenotypic differentiation are temporally separable events that precede cell fusion upon myogenesis. J Cell Biol 132:657-666.
53. Asada M, Yamada T, Ichijo H, et al. 1999. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J 18:1223-1234.
54. Cheng T, Rodrigues N, Shen H, et al. 2000. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 287:1804-1808.
55. Ullmannova V, Stockbauer P, Hradcova M, et al. 2003. Relationship between cyclin D1 and p21 (Waf1/Cip1) during differentiation of human myeloid leukemia cell lines. Leuk Res 2003; 27:1115-1123.